- Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome2021 | 2. lékařská fakulta
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | 1. lékařská fakulta
- Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial2018 | 1. lékařská fakulta
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes2021 | 1. lékařská fakulta
- Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic SyndromesPublikace bez příslušnosti k fakultě
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes2016 | 1. lékařská fakulta
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Přírodovědecká fakulta
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | 1. lékařská fakulta
- Výzkumná zpráva Fakultní nemocnice ke klinickému hodnocení AZA-MDS-003Publikace bez příslušnosti k fakultě
- RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS2022 | Přírodovědecká fakulta, 1. lékařská fakulta